Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Prolyl-4-hydroxylase 3 maintains β cell glucose metabolism during fatty acid excess in mice
Daniela Nasteska, Federica Cuozzo, Katrina Viloria, Elspeth M. Johnson, Alpesh Thakker, Rula Bany Bakar, Rebecca L. Westbrook, Jonathan P. Barlow, Monica Hoang, Jamie W. Joseph, Gareth G. Lavery, Ildem Akerman, James Cantley, Leanne Hodson, Daniel A. Tennant, David J. Hodson
Daniela Nasteska, Federica Cuozzo, Katrina Viloria, Elspeth M. Johnson, Alpesh Thakker, Rula Bany Bakar, Rebecca L. Westbrook, Jonathan P. Barlow, Monica Hoang, Jamie W. Joseph, Gareth G. Lavery, Ildem Akerman, James Cantley, Leanne Hodson, Daniel A. Tennant, David J. Hodson
View: Text | PDF
Research Article Endocrinology Metabolism

Prolyl-4-hydroxylase 3 maintains β cell glucose metabolism during fatty acid excess in mice

  • Text
  • PDF
Abstract

The α-ketoglutarate–dependent dioxygenase, prolyl-4-hydroxylase 3 (PHD3), is an HIF target that uses molecular oxygen to hydroxylate peptidyl prolyl residues. Although PHD3 has been reported to influence cancer cell metabolism and liver insulin sensitivity, relatively little is known about the effects of this highly conserved enzyme in insulin-secreting β cells in vivo. Here, we show that the deletion of PHD3 specifically in β cells (βPHD3KO) was associated with impaired glucose homeostasis in mice fed a high-fat diet. In the early stages of dietary fat excess, βPHD3KO islets energetically rewired, leading to defects in the management of pyruvate fate and a shift from glycolysis to increased fatty acid oxidation (FAO). However, under more prolonged metabolic stress, this switch to preferential FAO in βPHD3KO islets was associated with impaired glucose-stimulated ATP/ADP rises, Ca2+ fluxes, and insulin secretion. Thus, PHD3 might be a pivotal component of the β cell glucose metabolism machinery in mice by suppressing the use of fatty acids as a primary fuel source during the early phases of metabolic stress.

Authors

Daniela Nasteska, Federica Cuozzo, Katrina Viloria, Elspeth M. Johnson, Alpesh Thakker, Rula Bany Bakar, Rebecca L. Westbrook, Jonathan P. Barlow, Monica Hoang, Jamie W. Joseph, Gareth G. Lavery, Ildem Akerman, James Cantley, Leanne Hodson, Daniel A. Tennant, David J. Hodson

×

Figure 4

βPHD3KO in vivo and in vitro phenotype during early metabolic stress (4 weeks HFD).

Options: View larger image (or click on image) Download as PowerPoint
βPHD3KO in vivo and in vitro phenotype during early metabolic stress (4 ...
(A) Egln3 remains suppressed in βPHD3KO islets after 4 weeks HFD (n = 3–6 animals/genotype; unpaired t test). (B and C) Glucose tolerance (B) is impaired in male βPHD3KO mice after 4 weeks HFD, although fasting glucose levels (C) are unaffected after 72 hours HFD (n = 8–11 animals/genotype; 2-way RM ANOVA, Sidak’s test). (D) Body weight is similar in male HFD-fed βPHD3CON and βPHD3KO animals (n = 11–12 animals/genotype; 2-way RM ANOVA, Sidak’s test). Body weight data from Figure 2A are included for comparison. (E) Glucose tolerance is unaffected in male Cre-only and Egln3fl/fl-only controls (n = 10–13 animals/genotype; 2-way RM ANOVA, Tukey’s test). (F) Serum insulin levels after glucose challenge are similar in βPHD3CON and βPHD3KO mice (n = 7–13 mice/genotype; 2-way RM ANOVA, Sidak’s test). (G) Insulin responses to glucose, shown by stimulation index, are higher in male βPHD3KO mice (n = 7–13 animals/genotype; 2-way RM ANOVA, Sidak’s test). (H and I) Glucose-stimulated and Exendin-4–potentiated insulin secretion are increased in βPHD3KO islets (H) (n = 20 replicates, 4 animals/genotype; 2-way ANOVA, Sidak’s test), whereas insulin content (I) remains unchanged (n = 20 replicates, 4 animals/genotype; unpaired t test). (J) βPHD3CON and βPHD3KO mice show similar oral glucose tolerance (n = 7 animals/genotype; 2-way RM ANOVA, Sidak’s test). (K) No changes in body composition are seen in βPHD3KO vs. βPHD3CON mice (n = 4 animals/genotype; 2-way ANOVA, Sidak’s test). (L) Insulin sensitivity remains unchanged in βPHD3KO mice (n = 4–5 animals/genotype; 2-way RM ANOVA, Sidak’s test). Data shown as mean ± SEM. *P < 0.05, **P < 0.01, and NS. VAT/SAT/BAT, visceral/subcutaneous/brown adipose tissue; SC, standard chow; HFD, high-fat diet; IPGTT, i.p. glucose tolerance test.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts